Table 2. Multivariate analysis of... | American Society of Hematology

Table 2.

Multivariate analysis of effects of select prognostic variables and randomized treatment on overall survival and relapse-free survival on study

Survival	HR	95% CI	P value
Overall
Randomized treatment: Oral-AZA vs placebo	0.732	0.5898-0.9074	.004
NPM1 mutation status at diagnosis: NPM1^mut vs NPM1^wt	0.624	0.469-0.829	.001
FLT3 mutation status at diagnosis: FLT3^mut (ITD/TKD) vs FLT3^wt	1.444	1.023-2.039	.036
Cytogenetic risk at diagnosis: poor vs intermediate	1.853	1.376-2.495	<.001
MRD status at screening: MRD⁺ vs MRD^–	1.716	1.380-2.133	<.001
Relapse-free
Randomized treatment: Oral-AZA vs placebo	0.631	0.509-0.782	<.001
NPM1 mutation status at diagnosis: NPM1^mut vs NPM1^wt	0.614	0.467-0.808	<.001
FLT3 mutation status at diagnosis: FLT3^mut (ITD/TKD) vs FLT3^wt	1.034	0.727-1.472	.851
Cytogenetic risk at diagnosis: poor vs intermediate	1.753	1.294-2.375	<.001
MRD status at screening: MRD⁺ vs MRD^–	1.984	1.596-2.466	<.001

Survival	HR	95% CI	P value
Overall
Randomized treatment: Oral-AZA vs placebo	0.732	0.5898-0.9074	.004
NPM1 mutation status at diagnosis: NPM1^mut vs NPM1^wt	0.624	0.469-0.829	.001
FLT3 mutation status at diagnosis: FLT3^mut (ITD/TKD) vs FLT3^wt	1.444	1.023-2.039	.036
Cytogenetic risk at diagnosis: poor vs intermediate	1.853	1.376-2.495	<.001
MRD status at screening: MRD⁺ vs MRD^–	1.716	1.380-2.133	<.001
Relapse-free
Randomized treatment: Oral-AZA vs placebo	0.631	0.509-0.782	<.001
NPM1 mutation status at diagnosis: NPM1^mut vs NPM1^wt	0.614	0.467-0.808	<.001
FLT3 mutation status at diagnosis: FLT3^mut (ITD/TKD) vs FLT3^wt	1.034	0.727-1.472	.851
Cytogenetic risk at diagnosis: poor vs intermediate	1.753	1.294-2.375	<.001
MRD status at screening: MRD⁺ vs MRD^–	1.984	1.596-2.466	<.001